Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tumours

- PMLiVE

Ipsen eyes first-line licence for new advanced kidney cancer drug Cabometyx

Releases phase II data from head-to-head study with Pfizer's Sutent

- PMLiVE

Call for better patient-focused information in cancer

PatientView survey highlights shortcomings in explaining newer science

- PMLiVE

Pfizer to sell off Hospira’s infusions business – and its New York HQ

Infusion therapy specialist ICU Medical buys up unit in $1bn deal

- PMLiVE

Teva sells UK and Ireland assets to Intas Pharma for £603m

Generics portfolio and manufacturing facility gain set to double Indian firm’s UK sales

- PMLiVE

Reformed Cancer Drugs Fund backs its first drug – AZ’s Tagrisso

Lung cancer treatment will be available to NHS patients while NICE awaits data

- PMLiVE

Yoshinori Ohsumi wins Nobel Prize in Medicine for autophagy work

Receives the accolade for his discoveries of mechanisms for the cell process

AstraZeneca AZ

AZ licenses inflammatory bowel disease drug to Allergan for $1.52bn

Will receive $250m upfront with a further $1.27bn if drug reaches market in two indications

- PMLiVE

How merging firms can manage culture change

Addressing the potential problems and finding the solutions

Gilead Sciences

Gilead’s ulcerative colitis antibody flunks trial

Halts trial early as preliminary data shows no evidence of efficacy

- PMLiVE

AZ withdraws EU filing for ovarian cancer drug cediranib

Maintains cediranib’s value as a combination therapy despite EMA information request

- PMLiVE

The UK’s new Cancer Drugs Fund

"Clearer, faster decision-making" promised

- PMLiVE

Lilly closes on first approval for sarcoma drug Lartruvo

Orphan drug improved patient survival time by almost 12 months in phase II trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links